- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00005473
Cardiovascular Disease Trends 1980-91--A Gender Specific Perspective
Studie Overzicht
Toestand
Gedetailleerde beschrijving
BACKGROUND:
The Pawtucket Heart Health Program was a community-based research and demonstration project in cardiovascular disease prevention in the town of Pawtucket, Rhode Island and in the non-intervention comparison town of New Bedford, Massachusetts. The study was initiated by the NHLBI in August, 1980. See also Study 1022.
DESIGN NARRATIVE:
There were four major areas of analysis: 1) gender differences in trends from 1980 to 1991 in total event rates, hospital discharge rates, in-hospital case-fatality and out of hospital deaths for coronary heart disease (CHD) and stroke; 2) gender specific analyses of methodological issues which may affect the interpretation of morbidity and mortality surveillance data; 3) gender differences in the presentation, diagnosis, and treatment of CHD and stroke which may influence morbidity and mortality trends; and 4) gender differences in the association between population trends in risk factors and morbidity and mortality trends.
The study was conducted using morbidity and mortality data collected by the Pawtucket Heart Health Program between 1980 and 1993, and risk factor data obtained through biennial cross-sectional household health surveys conducted in random samples of residents in the two study communities. Morbidity and mortality data were obtained according to standardized epidemiologic surveillance methods. Hospitalized cases of coronary heart disease and stroke were identified through hospital discharge records and were validated using a standardized diagnostic algorithm based on data abstracted from medical records. Out-of-hospital deaths identified through death certificate data were validated using an algorithm based upon medical history data and information concerning the circumstances of death obtained from informant interviews.
Gender specific trends in both age-adjusted and age specific morbidity and mortality were compared. Trends in rates estimated from events classified according to ICD-9 discharge and death certificate codes were contrasted with those estimated from cases validated by standardized diagnostic algorithms. Data regarding circumstances of death and in-hospital treatment were assessed in relation to potential influences on morbidity and mortality trends. Absolute changes over time and average annual percent change over time were evaluated using linear and log-linear regression regression techniques. Other analytic methods included logistic regression and analysis of variance. Expected annual event rates in men and women were estimated from risk factor data using equations based upon accelerated failure time Weibull models, and the impact of risk factors on mortality rates was assessed by comparing predicted with actual rates.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Studietype
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Studie plan
Hoe is de studie opgezet?
Medewerkers en onderzoekers
Publicaties en nuttige links
Algemene publicaties
- Derby CA, Lapane KL, Feldman HA, Carleton RA. Trends in validated cases of fatal and nonfatal stroke, stroke classification, and risk factors in southeastern New England, 1980 to 1991 : data from the Pawtucket Heart Health Program. Stroke. 2000 Apr;31(4):875-81. doi: 10.1161/01.str.31.4.875.
- Derby CA, Lapane KL, Feldman HA, Carleton RA. Sex-specific trends in validated coronary heart disease rates in southeastern New England, 1980-1991. Am J Epidemiol. 2000 Feb 15;151(4):417-29. doi: 10.1093/oxfordjournals.aje.a010222.
- Derby CA, Lapane KL, Feldman HA, Carleton RA. Possible effect of DRGs on the classification of stroke: implications for epidemiological surveillance. Stroke. 2001 Jul;32(7):1487-91. doi: 10.1161/01.str.32.7.1487.
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 4956 (Egmont Foundation)
- R29HL055448 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hartziekten
-
University Hospital TuebingenVoltooidHeart Assist-apparaatDuitsland
-
University of ChicagoVoltooidHartfalen | Heart Assist-apparaat | HyponatremischVerenigde Staten
-
Region SkaneAanmelden op uitnodigingHartfalen New York Heart Association (NYHA) Klasse II | Hartfalen New York Heart Association (NYHA) Klasse IIIZweden
-
Carmel Medical CenterOnbekendPneumoperitoneum | Heart Output StoornisIsraël
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... en andere medewerkersNog niet aan het wervenHartfalen, systolisch | Hartfalen met verminderde ejectiefractie | Hartfalen New York Heart Association Klasse IV | Hartfalen New York Heart Association Klasse IIIPolen
-
Triple-Gene, LLCIntrexon Corporation; Precigen, IncVoltooidHart-en vaatziekten | Hartfalen | Heart-Assist-apparaatVerenigde Staten
-
University of WashingtonAmerican Heart AssociationVoltooidHartfalen, congestief | Mitochondriale verandering | Hartfalen New York Heart Association Klasse IVVerenigde Staten
-
Novartis PharmaceuticalsVoltooidPatiënten die de behandelingsperiode van 12 maanden van de kernstudie met succes hebben afgerond (de Novo Heart-ontvangers) die geïnteresseerd waren om behandeld te worden met EC-MPS
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc.VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases